ATE173933T1 - Verwendung eines lanthanoid-, zinn-, mangan-, yttrium-, kobalt-, barium-, strontiumsalzes für die herstellung einer pharmazeutischen zusammensetzung - Google Patents

Verwendung eines lanthanoid-, zinn-, mangan-, yttrium-, kobalt-, barium-, strontiumsalzes für die herstellung einer pharmazeutischen zusammensetzung

Info

Publication number
ATE173933T1
ATE173933T1 AT96402181T AT96402181T ATE173933T1 AT E173933 T1 ATE173933 T1 AT E173933T1 AT 96402181 T AT96402181 T AT 96402181T AT 96402181 T AT96402181 T AT 96402181T AT E173933 T1 ATE173933 T1 AT E173933T1
Authority
AT
Austria
Prior art keywords
yttrium
barium
cobalt
tin
disease
Prior art date
Application number
AT96402181T
Other languages
English (en)
Inventor
Lacharriere Olivier De
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of ATE173933T1 publication Critical patent/ATE173933T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96402181T 1995-10-26 1996-10-14 Verwendung eines lanthanoid-, zinn-, mangan-, yttrium-, kobalt-, barium-, strontiumsalzes für die herstellung einer pharmazeutischen zusammensetzung ATE173933T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9512657A FR2740342B1 (fr) 1995-10-26 1995-10-26 Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
ATE173933T1 true ATE173933T1 (de) 1998-12-15

Family

ID=9483958

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96402181T ATE173933T1 (de) 1995-10-26 1996-10-14 Verwendung eines lanthanoid-, zinn-, mangan-, yttrium-, kobalt-, barium-, strontiumsalzes für die herstellung einer pharmazeutischen zusammensetzung

Country Status (8)

Country Link
EP (1) EP0770391B1 (de)
JP (1) JPH09169656A (de)
AT (1) ATE173933T1 (de)
CA (1) CA2188891A1 (de)
DE (1) DE69601061T2 (de)
ES (1) ES2127612T3 (de)
FR (1) FR2740342B1 (de)
NO (1) NO964516L (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9621273D0 (en) 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
AT405017B (de) * 1997-10-06 1999-04-26 Jakoby Marie Luise Mittel zur stimulation der körpereigenen abwehr
GB0012487D0 (en) * 2000-05-24 2000-07-12 Pfylori Limited Use of metal compounds to treat gastrointestinal infections
DE10253634A1 (de) * 2002-11-13 2004-05-27 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Endoprothese
JP2007023010A (ja) * 2005-07-19 2007-02-01 Toshiro Azegami 閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
AU2006274821B2 (en) * 2005-07-29 2011-10-13 Consejo Superior De Investigaciones Cientificas Pharmaceutical compositions comprising a tungsten salt (VI) for the treatment of neurodegenerative disorders, particularly Alzheimer's disease and schizophrenia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB997975A (en) * 1964-01-31 1965-07-14 Aristotelis Papageorgiou Lambo Pharmaceutical compositions containing a cresol or a mixture of cresols
GB1209093A (en) * 1968-07-16 1970-10-14 Delandale Lab Ltd Pharmaceutical preparation
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
AU556817B2 (en) * 1982-02-03 1986-11-20 Efamol Limited Topical application of a lithium salt and dihomo-alpha- linolenic acid
MTP930B (en) * 1982-04-30 1984-04-10 Delandale Labs Ltd Substained release lithium-containing tablets and method for their manufacture
GB2133285A (en) * 1983-01-12 1984-07-25 Alec James Coppen Pharmaceutical compositions
GB8320203D0 (en) * 1983-07-27 1983-09-01 Horrobin D F Anti-viral compositions
AU599567B2 (en) * 1984-03-01 1990-07-26 Vernon Erk Method of treating memory disorders of the elderly
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
WO1988007060A1 (en) * 1987-03-19 1988-09-22 Arthropharm Pty. Limited Anti-inflammatory compounds and compositions
JPH01172325A (ja) * 1987-12-28 1989-07-07 Terumo Corp 抗リウマチ剤
JPH01287033A (ja) * 1988-05-13 1989-11-17 Terumo Corp 抗リウマチ剤
JPH03120220A (ja) * 1989-10-04 1991-05-22 Natterer Siegfried 調製薬剤およびその製造方法
JP3121859B2 (ja) * 1991-05-31 2001-01-09 利博 山瀬 抗ウイルス剤
HU207799B (en) * 1991-07-24 1993-06-28 Beres Export Import Rt Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis
JPH05117157A (ja) * 1991-09-04 1993-05-14 Kao Corp 象牙質知覚過敏予防・治療剤及びこれを含有する口腔用組成物
CA2208078C (en) * 1994-12-21 2009-06-23 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation

Also Published As

Publication number Publication date
DE69601061T2 (de) 1999-04-22
EP0770391B1 (de) 1998-12-02
EP0770391A3 (de) 1997-05-07
CA2188891A1 (fr) 1997-04-27
JPH09169656A (ja) 1997-06-30
FR2740342A1 (fr) 1997-04-30
NO964516D0 (no) 1996-10-24
EP0770391A2 (de) 1997-05-02
ES2127612T3 (es) 1999-04-16
NO964516L (no) 1997-04-28
DE69601061D1 (de) 1999-01-14
FR2740342B1 (fr) 1997-12-19

Similar Documents

Publication Publication Date Title
ATE201594T1 (de) Verwendung von venlafaxin oder eines aryloxy- propanaminderivates zur herstellung eines medikaments zur behandlung von inkontinenz
ATE178917T1 (de) Isocyanatprepolymere, ein verfahren zu ihrer herstellung und ihre verwendung
HUT73744A (en) Process for producing acetic acid
DE69611343D1 (de) Verwendung von Lanthanide-, Zinn-, Mangan-, Yttrium-, Kobalt-, Barium-, Strontiumsalzen in einem Hautpflegemittel
IL109684A0 (en) PHARMACEUTICAL COMPOUNDS FOR INHIBITING GASTRIC ACPharmaceutical compounds for inhibiting gastric acID SECRETION id secretion
CA2288751A1 (en) Encrustation and bacterial resistant coatings for medical applications
AU7129291A (en) Clear stick anti-perspirant
EP0442653A3 (en) Incorporation of desired groups into polymers, the polymers so produced, and compositions containing them
DE59505812D1 (de) Heisshärtende Einkomponenten-Polyurethan-Reaktivmassen und deren Verwendung
ATE173933T1 (de) Verwendung eines lanthanoid-, zinn-, mangan-, yttrium-, kobalt-, barium-, strontiumsalzes für die herstellung einer pharmazeutischen zusammensetzung
AU4015693A (en) Polysuccinimide polymers and process for preparing polysuccinimide polymers
DE59911076D1 (de) Verwendung einer wässrigen Bindemittelkombination zur Herstellung von physikalisch trocknenden Überzügen
ES2089199T3 (es) Composicion curable.
ES8505377A1 (es) Procedimiento para preparar amino acidos fosfonometilados
CA2060208A1 (en) Wound healing
DE3570639D1 (en) Method for the preparation of fine hexagonal ferrite powders, in particular, for magnetic recording
CA2035323A1 (en) Oxidation of tertiary-alkyl substituted aromatics
DE69200984T3 (de) Verfahren zur Herstellung eines Drahtes aus supraleitendem Oxid.
ATE261986T1 (de) Polyol-aminosäureverbindungen mit aktivität gegen helicobacter pylori
JPS6479181A (en) Novel beta-lactam compound and production thereof
DE69525439D1 (de) Antibiotikum und verfahren zu dessen herstellung
EP0623623A4 (de) Komplex von 2-aminäthansulfonsäure und zink.
DE68908474D1 (de) Polythioharnstoffe, verfahren zu ihrer herstellung und verwendung dieser polythioharnstoffe zur verhinderung oder herabsetzung der krustenbildung von polymerisationsreaktoren.
JPS54100497A (en) Curable polymer composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee